Home › Compare › EMAX vs JNJ

EMAX vs JNJ: Dividend Comparison 2026

EMAX yields 666666.67% · JNJ yields 3.36%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 EMAX wins by $8.275235618773884e+34M in total portfolio value
10 years
EMAX
EMAX
● Live price
666666.67%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$8.275235618773884e+34M
Annual income
$82,727,945,429,218,320,000,000,000,000,000,000,000,000.00
Full EMAX calculator →
JNJ
Johnson & Johnson
● Live price
3.36%
Share price
$147.50
Annual div
$4.96
5Y div CAGR
5.8%
Payout ratio
55%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.0K
Annual income
$827.78
Full JNJ calculator →

Portfolio growth — EMAX vs JNJ

📍 EMAX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodEMAXJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, EMAX + JNJ cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
EMAX pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

EMAX
Annual income on $10K today (after 15% tax)
$56,666,666.67/yr
After 10yr DRIP, annual income (after tax)
$70,318,753,614,835,575,000,000,000,000,000,000,000,000.00/yr
JNJ
Annual income on $10K today (after 15% tax)
$285.83/yr
After 10yr DRIP, annual income (after tax)
$703.61/yr
At 15% tax rate, EMAX beats the other by $70,318,753,614,835,575,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of EMAX + JNJ for your $10,000?

EMAX: 50%JNJ: 50%
100% JNJ50/50100% EMAX
Portfolio after 10yr
$4.137617809386942e+34M
Annual income
$41,363,972,714,609,160,000,000,000,000,000,000,000,000.00/yr
Blended yield
99.97%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

EMAX
No analyst data
Altman Z
-7.5
Piotroski
4/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
+55.1% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

EMAX buys
0
JNJ buys
0
No recent congressional trades found for EMAX or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricEMAXJNJ
Forward yield666666.67% ✓3.36%
Annual dividend / share$2.00$4.96 ✓
Payout ratio50% ✓55%
1-year div growth0%4.2% ✓
5-year div CAGR0%5.8% ✓
Portfolio after 10y$8.275235618773884e+34M$20.0K ✓
Annual income after 10y$82,727,945,429,218,320,000,000,000,000,000,000,000,000.00 ✓$827.78
Total dividends collected$8.275075881065991e+34M ✓$5.6K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: EMAX vs JNJ ($10,000, DRIP)

YearEMAX PortfolioEMAX Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$66,677,367$66,666,666.67$10,676$355.77+$66.67M → EMAX
2$415,506,651,117$415,435,306,334.37$11,407$389.39+$415506.64M → EMAX
3$2,419,908,598,386,268$2,419,464,006,269,573.00$12,198$426.53+$2419908598.37M → EMAX
4$13,171,697,643,084,456,000$13,169,108,340,884,183,000.00$13,056$467.62+$13171697643084.44M → EMAX
5$67,004,927,492,790,120,000,000$66,990,833,776,312,020,000,000.00$13,987$513.12+$67004927492790120.00M → EMAX
6$318,562,277,003,514,840,000,000,000$318,490,581,731,097,560,000,000,000.00$14,998$563.56+$318562277003514871808.00M → EMAX
7$1,415,484,168,853,553,000,000,000,000,000$1,415,143,307,217,159,200,000,000,000,000.00$16,098$619.52+$1.415484168853553e+24M → EMAX
8$5,878,130,573,362,507,000,000,000,000,000,000$5,876,616,005,301,833,000,000,000,000,000,000.00$17,295$681.69+$5.878130573362507e+27M → EMAX
9$22,813,793,009,840,743,000,000,000,000,000,000,000$22,807,503,410,127,248,000,000,000,000,000,000,000.00$18,599$750.82+$2.2813793009840744e+31M → EMAX
10$82,752,356,187,738,840,000,000,000,000,000,000,000,000$82,727,945,429,218,320,000,000,000,000,000,000,000,000.00$20,022$827.78+$8.275235618773884e+34M → EMAX

EMAX vs JNJ: Complete Analysis 2026

EMAX — Stock

Ecomax, Inc. does not have any significant operations. The company intends to seek new business opportunities or to engage in a merger or acquisition with an unidentified company. Previously, it operated a wet-cleaning process, a solution to dry cleaning methods. The company was formerly known as Ecomat, Inc. and changed its name to Ecomax, Inc. in May 2021. The company was incorporated in 1995 and is based in New York, New York. Ecomax, Inc. is a subsidiary of Clark Orient (BVI) Limited.

Full EMAX Calculator →

JNJ — Healthcare

Johnson & Johnson is a Dividend King with 62+ years of consecutive dividend increases. A healthcare conglomerate spanning pharmaceuticals, MedTech, and consumer health. JNJ spun off its consumer segment as Kenvue in 2023, focusing on higher-margin pharma and medical devices.

Full JNJ Calculator →
📬

Get this EMAX vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

EMAX vs SCHDEMAX vs JEPIEMAX vs OEMAX vs KOEMAX vs MAINEMAX vs ABBVEMAX vs MRKEMAX vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.